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Abstract
Background: Qian-Yu decoction (QYD) is a traditional Chinese medicinal recipe composed of Radix astragali (Astragalus
membranaceus (Fisch.) Bunge var. mongholicus (Bunge) P.K. Hsiao, Fabaceae), Herba epimedii (Epimedium brevicornum
Maxim., Berberidaceae), Herba leonuri (Leonurus japonicus Houtt., Lamiaceae), Cortex phellodendri (Phellodendron chinense
Schneid., Rutaceae) and Radix achyranthis bidentatae (Achyranthes bidentata Bl., Amaranthaceae). This study aimed to
evaluate the therapeutic activity of QYD against carrageenan-induced chronic prostatic/chronic pelvic pain syndrome
(CP/CPPS) in rats and further elucidate its effective components.
Methods: Three types of components, total polysaccharides, total flavonoids and total saponins were separately
extracted from QYD. Carrageenan-induced CP/CPPS rats were intragastrically administered with lyophilized product of
QYD, individual extracts and all the combined forms of extracts for three weeks. Prostatic index (PI) was determined and
histopathological analysis was performed. The levels of tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β),
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PEG2) in rat prostate tissues were measured using ELISA. The production
of inducible nitric oxide synthase (iNOS) was evaluated by an enzymatic activity assay, and the release of nitric oxide (NO)
was determined by a nitrate/nitrite assay.
Results: Treatment with QYD significantly ameliorated the histological changes of CP/CPPS rats and reduced the PI by
44.3%, with a marked downregulation of TNF-α (42.8% reduction), IL-1β (45.3%), COX-2 (36.6%), PGE2 (44.2%),
iNOS (54.1%) and NO (46.0%). Each of three extracts attenuated the symptom of CP/CPPS, but much more weakly than
QYD. The combined administration of three extracts showed efficacy comparable to that of QYD while better than that
of any combination of two extracts. A principal component analysis of the six inflammatory mediators as variables
indicated that the effects of TS on CP/CPPS were rather different from those of TF and TP, which were similar.
Conclusions: QYD can be beneficial in prevention and treatment of CP/CPPS. Polysaccharides, flavonoids and saponins,
as the major effective components of QYD, exert a cooperative effect on CP/CPPS.
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Background
Chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS), characterized by long-term pelvic or perineal
pain without evidence of urinary tract infection, accounts
for 90-95% of prostatitis cases [1]. As category III prostatitis
classified by the National Institute of Health, CP/CPPS has
been subdivided into inflammatory (category IIIa) and
non-inflammatory (category IIIb) forms, depending on
whether white blood cells can be found in semen, post-
prostatic massage urine and expressed prostatic secretion
of patients [2]. However, recent studies have questioned the
differentiation between categories IIIa and IIIb, since both
categories have increases in markers of inflammation, such
as tumor necrosis factor alpha (TNF-α), interleukin-1beta
(IL-1β), nitric oxide (NO), cyclooxygenase-2 (COX-2) and
prostaglandin E2 (PGE2) [3–7]. CP/CPPS is now thought
to result from an interplay between psychological factors
and dysfunctions in the immune, neurological and endo-
crine systems [8]. Yet still, the exact cause is unknown, and
treating is difficult.
The conventional treatments for CP/CPPS are antibi-
otics, alpha blockers, anti-inflammatory medications and
muscle relaxants, often combined with psychological
and physical therapies [9]. However, they focus on reliev-
ing symptoms rather than curing the condition, and are
often found to provide little or only temporary symptom
relief. Successful management of CP/CPPS has always
been a challenge for both urologists and patients.
Phytotherapy has gained increasing popularity with CP/
CPPS patients around the world, due to unique mecha-
nisms of action, very few side effects, low cost and high
patient acceptance. Two phytotherapeutic agents,
quercetin (a natural flavonoid) and cernilton (pollen ex-
tracts), have been valued as effective treatments on the
basis of clinical evidences [10–12].
Qian-Yu decoction (QYD), a traditional herbal recipe
consisting of (Radix astragali Astragalus membranaceus.
(Fisch.) Bunge var. mongholicus (Bunge) P.K. Hsiao, Faba-
ceae), Herba epimedii (Epimedium brevicornum Maxim.,
Berberidaceae), Herba leonuri (Leonurus japonicus Houtt.,
Lamiaceae), Cortex phellodendri (Phellodendron chinense
Schneid., Rutaceae) and Radix achyranthis bidentatae
(Achyranthes bidentata Bl., Amaranthaceae), was pre-
scribed for treating CP/CPPS according to the clinical
experience of traditional Chinese medicine (see Table 1).
Our previous work pointed out that QYD had efficacy in
relieving inflammation and pain, promoting blood circula-
tion to remove stasis and increasing immunity in rat
models [13]. Many in vitro and in vivo studies have
reported that each herbal ingredient of QYD possesses
anti-inflammatory effects [14–19]. But, it remains unclear
how effective QYD treatment is for CP/CPPS.
Therefore, the aim of this study is to evaluate the
therapeutic activity of QYD on CP/CPPS and elucidate
its effective components. To this end, three types of
chemical components, total polysaccharides (TP), total
flavonoids (TF) and total saponins (TS), were extracted
from QYD. The effects of QYD and its extracts on pros-
tatic index (PI), histological change and production of
some inflammatory markers (TNF-α, IL-1β, COX-2,
PGE2, inducible nitric oxide synthase (iNOS) and NO)
in carrageenan-induced CP/CPPS rats were investigated.
Note that the extract types were defined according to
the most studied active components of the herbal ingre-
dients. Since the content of total alkaloids in QYD had
been found to be extremely low, which might be attrib-
uted to their insolubility and instability during decocting
[20], alkaloids were not taken into consideration here.
Methods
Plant materials and chemicals
Dried herbal materials Radix astragali, Herba epimedii,
Herba leonuri, Cortex phellodendri and Radix achyr-
anthes were purchased from SinoPharm Group (Wuhan,
China) and identified by Prof. Yonggang Chen, one of
the coauthors. Their voucher specimens have been
deposited at the herbarium of the Department of
Pharmacy in Wuhan Third Hospital. All chemical reagents
were purchased from SinoPharm Chemical Reagent
(Shanghai, China), and of highest available purity.
Preparation of Qian-Yu decoction
Dry herbal materials (100 g) of QYD were weighed out
and put into a regular stainless steel pot. One liter water
was added to cover the herbs completely. After over-
night soaking, the herbs were brought to a rolling boil,
and then simmered for 2 h. The liquid was strained and
the herbs were kept in the pot for the second cook. One
liter water was added, boiled out, and then kept simmer-
ing for 2 h again. The liquid was strained and added to
that from the initial cook. The combined liquid was
concentrated to produce the QYD (100 ml). The lyophi-
lized product (DLP) of the QYD weighed 28.20 g. The
TP, TF and TS contents of DLP were determined using
the methods as described below.
HPLC analysis
Chromatographic fingerprint analysis was performed in a
Dionex UltiMate 3000 HPLC system (Thermo Scientific,
Table 1 Composition of Qian-Yu decoction
Herbal ingredients Chinese names Percentage (%)
Radix astragali Huangqi (黄芪) 40
Herba epimedii Yinyanghuo (淫羊藿) 20
Herba leonuri Yimucao (益母草) 20
Cortex phellodendri Huangbo (黄柏) 10
Radix achyranthis bidentatae Niuxi (牛膝) 10
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Germering, Germany) equipped with a dioxide array
detector (DAD). The separation was conducted on a
Hypersil Gold C18 column (4.6 mm× 250 mm, 5.0 μm;
Thermo Scientific, Waltham, MA, USA) at 25 °C. The
mobile phase was composed of (A) 0.1% formic acid-
water solution and (B) methanol in a gradient program:
8.0-40.0% B, 0–15 min; 40.0-65.0% B, 15–35 min; 65.0-
92.0% B, 35–45 min; 92.0% B, 45–55 min. The flow rate
was set at 1.00 ml/min and the injection volume was
20 μl. The detection wavelength of 254 nm was used.
Extraction of total polysaccharides
Qian-Yu decoction was mixed with 95% ethanol to an
ethanol concentration of 80%. The mixture was kept at
room temperature overnight, and filtered to collect the
precipitated crude polysaccharides and the supernatant
from which flavonoids were further separated. The crude
polysaccharides were added to hot water, and the undis-
solved part was removed by filtering. After cooling, the
solution was deproteinized using the Sevag reagent
(CHCl3: n-butanol = 4:1, v/v) [21]. The resulting solution
was purified via dialysis (COMW= 14,000 Da) for 18 h,
and subjected to lyophilization to produce the final TP
extract (Fig. 1).
The content of TP in the extract was determined by
the phenol-sulfuric acid colorimetric method using
glucose (Must Biotechnology, Chengdu, China) as the
standard [22]. Briefly, aqueous solution of glucose
(1.00 mg/ml) was diluted to a series of concentrations
(0.01-0.05 mg/ml). Aliquots (2 ml) of these solutions
were transferred into test tubes with caps. After addition
of 5% aqueous phenol solution (1 ml) and concentrated
sulfuric acid (5 ml), the mixture was fully shaked, and
then kept for 5 min at room temperature followed by
15 min incubation at 90 °C in a water bath. The absorb-
ance of the resulting solution at 490 nm was read by an
UV–vis spectrophotometer (UV-1800; Shimadzu,
Kyoto, Japan) with distilled water as the blank. The
obtained standard curve over a range of 0.01-0.05 mg/ml
was Y = 5.542X + 0.083 with a squared regression coeffi-
cient (R2) of 0.992, where Y was the absorbance and X
was the concentration of glucose. The content of TP was
expressed as glucose equivalents.
Extraction of total flavonoids
The supernatant of QYD after ethanol precipitation was
evaporated under reduced pressure. The obtained dry
sample was dissolved in deionized water, followed by
adjustment of pH to 9.0 using 1.0 M NaOH solution.
The solution was washed three times with chloroform,
adjusted to pH 3.0 by 1.0 M HCl solution and loaded
onto a polyamide resin (polycaprolactam type; Yoko,
Wuhan, China) column. The column was flushed with 5
bed volumes of ionized water and 50% ethanol, with the
latter eluate gathered. After removing the solvent, the
final TF extract was obtained (Fig. 1).
The content of TF in the extract was determined by
UV–vis spectrophotometry at 270 nm with icariin (Must
Fig. 1 Extraction procedures of total polysaccharides, total flavonoids and total saponins from QYD
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Biotechnology, Chengdu, China) as the standard and metha-
nol as the vehicle, as detailed in the entry ‘Yinyanghuo’ of
Chinese Pharmacopeia (2015, volume 1). The obtained
standard curve was Y = 36.709X+ 0.018 (R2 = 0.998). In the
equation, Y was the absorbance and X was the icariin
concentration, and the linear range was 0.002-0.012 mg/ml.
The TF content was expressed as icariin equivalents.
Extraction of total saponins
Qian-Yu decoction was washed three times with petrol-
eum ether to remove the non- and low-polar fractions,
and then treated with water saturated n-butanol to
extract saponins. The resulting organic phase was evapo-
rated under reduced pressure and the crude saponins
were obtained as a thick liquid. The sample was loaded
into a macroporous adsorption resin (Type D101; Sino-
Pharm Chemical Reagent, Shanghai, China) column via
a dry-loading method. After washing the column with 5
bed volumes of deionized water and 30% ethanol, sapo-
nins were eluted using 5 bed volumes of 70% ethanol.
The eluent was evaporated under low pressure to give
the saponin extract (Fig. 1).
The TS content of the extract was tested by a vanillic
aldehyde-perchloric acid colorimetric method with astra-
galoside IV (Must Biotechnology, Chengdu, China) as the
standard [23]. The standard solutions of astragaloside IV
in methanol at varying concentrations (0.25-1.00 mg/ml)
were prepared. Aliquots (1.0 ml) of standard solutions
were transferred into volumetric flasks (25 ml), and 0.5%
vanillic aldehyde-acetic acid (1 ml) and perchloric acid
(4 ml) were added. After shaking, the mixtures were
heated at 60 °C for 10 min in a water bath, then cooled in
an ice water bath, and finally diluted with methanol to a
defined volume (25 ml). The absorbance of the resulting
solutions at 554 nm was measured with sample-free
solution as the blank. The standard curve was obtained as
Y = 0.515X + 0.086 (R2 = 0.997), where Y was the absorb-
ance and X was the astragaloside IV concentration. The
linear range was 0.25-1.00 mg/ml. The content of TS was
expressed as astragaloside IV equivalents.
Animals
Male specific-pathogen-free (SPF)-bred Sprague–Daw-
ley rats, aged eight weeks and weighed 180–220 g,
were purchased from the Hubei Center for Diseases
Control and Prevention (Wuhan, China). All rats were
individually housed under SPF conditions at 22 ± 2 °C
on a 12 h light/dark cycle, and fed using standard rat
chow and water ad libitum. They were allowed one
week of acclimatization prior to experiments. All
animal protocols were approved by the Animal Ethics
Committee of Wuhan Third Hospital, and conducted
in uniformity with national guidelines of the care and
use of laboratory animals.
Acute toxicity study
In the preliminary examination, the median lethal dose
(LD50) of DLP was not able to be found due to low
toxicity. The maximum feasible dose (12.00 g/kg) was
intragastrically administered to 20 male Sprague–Dawley
rats, which were kept fasting and given water only for
overnight before administration. The animals were
observed to record mortality, toxic symptoms and body
weight for 14 days after administration. At the 14th day,
gross necropsies were performed on all animals.
Induction of CP/CPPS in rats and treatment regimens
Rats were randomized into groups (10 rats per group): the
normal group, the sham group, the model group, the posi-
tive control group and treatment groups, i.e., QYD, TP,
TF, TS and any combination of extracts: polysaccharides-
flavonoids-saponins (PFS), flavonoids-saponins (FS),
polysaccharides-flavonoids (PF), polysaccharides-saponins
(PS) combinations. The rats in the model, positive control
and treatment groups were induced by carrageenan to
CP/CPPS rats as described previously [24]. Briefly, both
right and left ventral lobes of the prostate gland were
injected with 0.1 ml sterile solution of 1.0% carrageenan.
For the sham group, carrageenan solution was replaced by
an equal volume of saline. All surgery was performed
under isoflurane anesthesia (5% for induction and 3% for
maintenance), and all efforts were made to minimize suf-
fering. One week later, the rats in the treatment groups
were intragastrically administered (1.0 ml/100 g) with
DLP (3.00 g/kg), TP (482.3 mg/kg), TF (339.7 mg/kg), TS
(380.2 mg/kg) and the extract combinations (e.g., PFS:
(482.3 mg TP + 339.7 mg TF + 380.2 mg TS)/kg) once per
day for three weeks, respectively. The dose of each extract
was derived from DLP dose and the contents of the corre-
sponding components in DLP and the extract. Cernilton
(100.0 mg/kg) was given to the positive control group and
saline to the normal, sham and model groups.
Body weight, food and water consumption by animals
in each group were measured once each week. No death
or abnormal behavior was observed during the course of
the study. After final administration, the rats were
starved for 12 h, weighed, and finally euthanized by car-
bon dioxide inhalation. The ventral prostates of rats
were harvested and weighed instantly. Prostatic index
was calculated as the ratio of prostate weight to body
weight (mg/g). Each prostate was dissected into two
halves, and one was fixed in 10% neutral buffered forma-
lin for histological examination and the other was stored
at −80 °C until use.
Histological examination
After 24-h fixation, the tissues were gradually dehy-
drated in ethanol and embedded in paraffin, and then
cut with a microtome into 5–6 μm thick paraffin
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sections. The sections were subjected to routine staining
with hematoxylin and eosin (H&E) and examined under
a light microscope.
Measurements of TNF-α, IL-1β, COX-2 and PGE2
Frozen tissues were rinsed three times with ice cold
saline. Known weights of the tissues were homoge-
nized in cold 0.1 M Tris–HCl buffer (pH7.4) at 4 °C
to give 10% homogenates (w/v), and centrifuged at
3000 × g for 20 min at 4 °C. The supernatants were
stored at −20 °C until used. TNF-α, IL-1β, COX-2
and PGE2 in the supernatant were measured using
commercial ELISA assay kits (TNF-α, IL-1β: Neo-
bioscience, Shanghai, China; COX-2, PEG2: Cusabio,
Wuhan, China), according to the manufacturers’ in-
structions. The assay tested each sample in triplicate.
The results are expressed as pg/ml.
Measurements of NO and iNOS
The measurements of NO and iNOS in the above
homogenate supernatant were performed with nitrate/
nitrite assay kits and enzymatic activity assay kits
(Nanjing Jiancheng Bioengineering Institute, Nanjing,
China), respectively, in line with the recommended
procedures. Each sample was measured in triplicate.
The level of NO is expressed as μmol/g, and the ac-
tivity of iNOS is expressed as U/mg protein.
Statistical analysis
All values are given as means ± standard deviations (S.D.).
Statistical analysis was carried out using one-way analysis
of variance (ANOVA) test, followed by Turkey’s post hoc
test. P < 0.05 was considered statistically significant.
Results
Contents of TP, TF and TS
Using spectrophotometric and colorimetric methods, the
TP, TF and TS contents of DLP were found to be 11.3%,
6.2% and 8.2%. After TP, TF and TS were separately
extracted from QYD, their contents in the extracts
reached up to 69.0%, 63.4% and 53.6%, respectively. The
HPLC fingerprint analysis of QYD was conducted, as
shown in Fig. 2.
Acute toxicity of Qian-Yu decoction
No mortality and no sign of toxicity were observed in
14 days after the administration of the maximum
feasible dose (12.00 g/kg) of DLP. Gross necropsies indi-
cated no apparent lesions in the major organs of
animals. The doses up to 12.00 g/kg were considered as
Fig. 2 Fingerprint analysis of QYD using HPLC. a chromatogram of QYD lyophilized product (DLP); b chromatogram of standard references, (1)
baicalin, (2) icariin, (3) formononetin and (4) wogonin; c chromatogram of the solvent (blank). The signals were monitored at 254 nm
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safe. Based on the results, the doses of 1.50, 3.00, 6.00 g/kg
were selected for further evaluation of therapeutic activity
on CP/CPPS.
Prostatic index and histopathological analysis
At first, we compared the effects of different doses of
DLP (1.50, 3.00, 6.00 g/kg) on the PI levels and histo-
pathology of CP/CPPS rats, as illustrated in Fig. 3.
Obviously, the level of PI for the model group had a sig-
nificant increase as compared with that for the sham
group, while there was no significant difference between
the sham and normal groups (Fig. 3a). The severity of
condition in each group was histologically evaluated in
terms of lymphocyte infiltration, morphological change
of prostate acini and interstitial fibrosis (Fig. 3b). It can
be seen that in contrast to the normal and sham groups
without signs of inflammation, the model group was
characterized by focal lymphocyte infiltration in the
stroma, notably increased epithelial height, frequent
luminal in-foldings, significant reduction of acinar
diameter and enhanced interstitial proliferation. This
confirmed the successful establishment of CP/CPPS
model. Treatment with DLP at the doses of 1.50, 3.00,
6.00 g/kg significantly decreased PI levels and amelio-
rated the histopathological alternations of rat prostates.
Moreover, DLP at the doses of 3.00, 6.00 g/kg were
clearly more effective than that at the dose of 1.50 g/kg,
and increasing the dose of DLP from 3.00 to 6.00 g/kg
failed to improve its therapeutic activities. Therefore, the
DLP dose of 3.00 g/kg was used for the decoction group
in the following study.
The effect of TP, TF, TS in QYD and their combined
forms on the symptoms of CP/CPPS was further investi-
gated, as shown in Figs. 4 and 5. The intragastric admin-
istration of TP, TF and TS reduced the PI level of CP/
CPPS rats by 3.8%, 20.6% and 28.2%, respectively, while
the PFS group showed the closest PI to the decoction
group (Fig. 4). The PI level of the decoction group was
in close proximity to that of the cernilton group. Also,
Fig. 5 indicates that the histological changes of CP/CPPS
rats were suppressed by the extracts and their combined
therapies, and PFS had the most obvious effect. Treat-
ment with QYD was very comparable to that with
cernilton, resulting in a marked symptom amelioration.
Effects of QYD and its extracts on TNF-α and IL-β
The levels of TNF-α and IL-β in the rat ventral prostates
of the model group were found to be much higher than
those of the sham group (Fig. 6). The TNF-α and IL-β
levels of the treatment groups exhibited varying
decreases of 7.1% to 42.8% and 6.8% to 45.3% as
compared with the model group, with those for the
decoction group and the PFS group the lowest. The de-
coction group had lower levels of TNF-α and IL-β than
the cernilton group, and the PFS group had no signifi-
cant difference from the cernilton group.
Effects of QYD and its extracts on COX-2, PGE2, iNOS and
NO
As illustrated in Fig. 7, the levels of COX-2, PGE2, iNOS
and NO in the rat ventral prostates of the model group
were significantly upregulated when compared to the
sham group, and the upregulation was attenuated by
treatments with the test samples. The decoction group
exhibited the lowest prostatic levels of PGE2, iNOS and
NO among the treatment groups, while the COX-2 level
of the PFS group was lower than those of the others.
However, the effect of PFS on the production of these
inflammatory mediators only had a small difference from
that of QYD.
Discussion
Qian-Yu decoction is a traditional herbal recipe consisting
of five frequently used Chinese herbs, i.e., Radix astragali,
Herba epimedii, Herba leonuri, Cortex phellodendri and
Radix achyranthis bidentatae. As prescribed on clinical
Fig. 3 Prostatic indexes (a) and histopathological sections (b) of carrageenan-induced CP/CPPS rats after treatments of different doses (1.50, 3.00,
6.00 g/kg) of QYD lyophilized product (DLP). All the sections were stained with hematoxylin and eosin, and observed under light microscope at
100× original magnification. ap < 0.01when compared with the sham group; bp < 0.05 when compared to the model group
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knowledge of traditional Chinese medicine, radix astragali
and herba epimedii accounting for 60% of the total herbal
weight were expected to function as the primary ingredi-
ents, and the rest assists in managing the condition. In
this study, the therapeutic effect of QYD on carrageenan-
induced CP/CPPS in rats was investigated. Injection of
carrageenan led to increased PI level and abnormal
prostatic histology in line with the previous observations
[25, 26], as well as upregulation of inflammatory markers,
which demonstrated a successfully established CP/CPPS
model. Carrageenan is a highly sulfated polygalactan with
15-40% of ester-sulfate content and an average molecular
weight well above 100 kDa [27]. Carrageenan has been
widely used to induce inflammation in animal models and
human cells [28, 29]. Carrageenan triggers inflammatory
cascades in which Toll-like receptor 4 (TLR4) and B-cell
leukemia/lymphoma 10 (BCL10) are critical [30, 31]. The
inflammatory response initiated by carrageenan exposure
activates both canonical, involving RelA (p65) and p50,
and non-canonical, involving RelB and p52, pathways of
nuclear factor kappa B (NF-κB) activation.
The treatment with QYD markedly decreased the level
of PI and attenuated the histological changes of prostatic
tissues. Moreover, the production of TNF-α and IL-β
were significantly reduced in the decoction group, as
was the case for COX-2, PGE2, iNOS and NO. The
efficacy of QYD was highly comparable to that of cernil-
ton, which is a recognized phototherapeutic agent of
Fig. 4 Prostatic indexes of carrageenan-induced CP/CPPS rats after
three-week oral administration of QYD and its extracts. Decoction, rats
treated with QYD lyophilized product (3.00 g/kg); TP, TF, TS, PFS, FS, PS
and PF, rats treated with total polysaccharides (482.3 mg/kg),
total flavonoids (339.7 mg/kg), total saponins (380.2 mg/kg) from
QYD and their combined forms, i.e., polysaccharides-flavonoids-saponins,
flavonoids-saponins, polysaccharides-saponins and polysaccharides-
flavonoids combinations. All values are given as means ± S.D. ap< 0.01,
when compared with the sham group; bp < 0.01, cp < 0.05 when
compared with the model group
Fig. 5 Histopathologic sections of the ventral prostates of carrageenan-induced CP/CPPS rats from different treatment groups. Decoction, rats treated with
QYD lyophilized product (3.00 g/kg); TP, TF, TS, PFS, FS, PS, PF, rats treated with total polysaccharides (482.3 mg/kg), total flavonoids (339.7 mg/kg), total
saponins (380.2 mg/kg) from QYD and their combined forms, i.e., polysaccharides-flavonoids-saponins, flavonoids-saponins, polysaccharides-saponins and
polysaccharides-flavonoids combinations. Sections were stained with hematoxylin and eosin, and photographed at 100× original magnification
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CP/CPSS. Therefore, QYD can be beneficial in treating
CP/CPPS.
The extracts from QYD, TP, TF and TS, individually
attenuated the symptom of CP/CPPS in rats, but obvi-
ously more weakly than QYD. Among them, TS
suppressed the production of TNF-α, IL-1β, iNOS and
NO more effectively, while the treatments with TP and
TF resulted in relatively significant reduction in the
levels of COX-2 and PGE2, respectively. The findings
are in agreement with the previous works [32–37]. For
instance, astragalus saponins inhibited the production of
TNF-α, the overexpression of iNOS and the subsequent
Fig. 6 Effects of QYD and its extracts on prostatic TNF-α (a) and IL-β (b) levels of carrageenan-induced CP/CPPS rats. Decoction, rats treated with QYD
lyophilized product (3.00 g/kg); TP, TF, TS, PFS, FS, PS and PF, rats treated with total polysaccharides (482.3 mg/kg), total flavonoids (339.7 mg/kg), total
saponins (380.2 mg/kg) from QYD and all of their combined forms, i.e., polysaccharides-flavonoids-saponins, flavonoids-saponins, polysaccharides-
saponins and polysaccharides-flavonoids combinations. Values are presented as means ± S.D. ap < 0.01, when compared with the sham group;
bp < 0.01, cp < 0.05 when compared with the model group
Fig. 7 Effects of QYD and its preparative extracts on prostatic COX-2 (a), PGE2 (b), iNOS (c) and NO (d) levels of carrageenan-induced CP/CPPS rats.
Decoction, rats treated with QYD lyophilized product; TP, TF, TS, PFS, FS, PS and PF, rats treated with total polysaccharides, total flavonoids,
total saponins extracted from QYD and all of their combined forms, i.e., polysaccharides-flavonoids-saponins, flavonoids-saponins, polysaccharides-
saponins and polysaccharides-flavonoids combinations. All values are given as means ± S.D. ap < 0.01, when compared with the sham group; bp < 0.01,
cp < 0.05 when compared with the model group
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generation of NO in lipopolysaccharide (LPS)-stimulated
mouse macrophage RAW264.7 [32]. In the same model,
astragalus flavonoids reduced the release of TNF-α,
IL-1β and NO in a dose-dependent manner [33]. More-
over, the presence of astragalus polysaccharides
downregulated the expression of TNF-α and IL-1β in
LPS-infected Caco2 cells and COX-2 expression in
HepG2 cells [34, 35]. Guo et al. studied the protective
effect of icariin, a major flavonoid of herba epimedii, on
a rat model with brain dysfunction (inflammation)
induced by LPS [36]. Their results showed that the
expression of TNF-α, IL-1β and COX-2 in brain was sig-
nificantly reduced by icariin. Also, icariin inhibited the
mRNA expression of TNF-α, COX-2 and iNOS and
further suppressed the secretion of TNF-α, PGE2 and
NO in the lung of LPS-treated mice [37]. Recent studies
suggested that the effects of the three extracts on modu-
lating these inflammatory mediators might be more or
less associated with inactivation of NF-κB [22, 37–41]. It
has been well known that NF-κB activation upregulates
gene expression of various inflammatory cytokines (e.g.,
TNF-α, IL-1β) and enzymes (e.g., COX-2, iNOS) [42, 43].
Meanwhile, TNF-α and IL-1β, as the key mediators of
inflammatory response, also activate NF-κB and stimulate
their own production and the production of other inflam-
matory mediators (including iNOS and COX-2) [44–46].
The upregulation of iNOS and COX-2 leads to increased
synthesis of NO and PGE2.
Despite weak effects of individual extracts, the combined
administration of three extracts demonstrated efficacy com-
parable to that of QYD while better than that of any com-
bination of two extracts. Therefore, all three extracts
contribute to the therapeutic effect of QYD on CP/CPPS,
and constitute the major part of its effective components.
A very useful way to compare the therapeutic effects
of the test samples is to perform a principal component
analysis (PCA) using all six markers of inflammation
(TNF-α, IL-β, COX-2, PGE2, iNOS and NO) as vari-
ables. PCA can convert a set of possibly correlated
variables into a set of linearly uncorrelated variables
called principal components (PCs) that contain exactly
the same information. The first few PCs usually contain
the vast majority of the information in the data so that
the dimensionality of the data can be reduced. In the
present case, the first two PCs accounted for 96.5% of
the total variance in our data. A plot of the scores of the
second PC versus the first PC revealed how close the
inflammatory states of the animal groups were in terms
of the distance between the points in the two-dimensional
plot, see Fig. 8. It can be easily seen that the point for the
decoction group is closer to the sham group than the cer-
nilton group, and the PFS group is quite close to the sham
and decoction groups. Very interestingly, the TP, TF and
TS groups stay far away from the sham group in similar
distances, while the TS group is distant from the TP and
TF groups, which stay close to each other. This reveals
that the effects of TS on CP/CPPS are rather different
from those of TF and TP. Thus, there is a cooperative
effect among these three extracts involved in the thera-
peutic mechanism of QYD [47, 48].
Conclusion
In the present study, the therapeutic activity of QYD
and its three preparative extracts (i.e., TP, TF and TS)
against CP/CPPS was investigated on carrageenan-
induced rat models. The results showed that QYD had a
potent therapeutic activity on CP/CPPS, which was even
slightly stronger than the popular plant extract, cernil-
ton. The individual extracts exerted a weak efficacy at
the same doses as contained in a dose of decoction,
whereas the combined therapy with the three extracts
produced a comparable effect to the decoction. Hence,
QYD may be considered as an effective treatment option
for CP/CPPS, and polysaccharides, flavonoids and
saponins make up its major effective components. Note
that the components we discussed in the decoction
might differ from the original components of the herbs
in the prescription, because of unavoidable chemical
changes when decocting [49]. In the future, we will do
more work to identify the principal individual effective
components of QYD.
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